Abstract
Interim Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with Untreated Acute Myeloid Leukemia (AML)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have